Suppr超能文献

中重度持续性哮喘患者哮喘恶化对医疗成本的影响。

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

机构信息

Analysis Group, Inc, New York, NY 10020, USA.

出版信息

J Allergy Clin Immunol. 2012 May;129(5):1229-35. doi: 10.1016/j.jaci.2012.01.039. Epub 2012 Feb 11.

Abstract

BACKGROUND

Health care costs increase in patients with more severe asthma, but the effect of asthma exacerbations on costs among patients with more severe asthma has not been quantified.

OBJECTIVE

This study compared direct health care costs between patients with moderate/severe persistent asthma with and without exacerbations.

METHODS

Patients who had an asthma diagnosis (International Classification of Diseases-ninth revision-Clinical Modification code 493.x), were 12 to 64 years old, and were receiving controller therapy were identified from a large administrative claims database. Patients were categorized as having moderate/severe persistent asthma and were further evaluated for exacerbations during a 12-month exacerbation identification period. Patients with 1 or more exacerbations (asthma-related inpatient or emergency department visit or corticosteroid prescription) were matched to patients without exacerbations on demographic characteristics and asthma severity. Total and asthma-related health care costs during the 1-year study period after the exacerbation index date were calculated.

RESULTS

Patients with exacerbations had significantly higher total health care costs ($9223 vs $5011, P < .0001) and asthma-related costs ($1740 vs $847, P < .0001). The cost differences remained significant after controlling for patient differences by using multivariate models. Patients with exacerbations (n = 3830) had higher rates of sinusitis, allergy-related diagnoses or medications, pneumonia, and mental disorders and higher average Charlson Comorbidity Index scores at baseline. Patients with exacerbations filled their prescriptions for controllers more often and had higher asthma-related drug costs.

CONCLUSIONS

Patients with moderate/severe persistent asthma who had exacerbations had higher total and asthma-related health care costs than those without exacerbations. Moreover, controller medication use was higher in patients with exacerbations.

摘要

背景

健康护理费用在病情较重的哮喘患者中增加,但尚未量化哮喘加重对病情较重哮喘患者成本的影响。

目的

本研究比较了有和无哮喘加重的中重度持续性哮喘患者的直接健康护理成本。

方法

从一个大型行政索赔数据库中确定了有哮喘诊断(国际疾病分类第 9 版临床修订版代码 493.x)、年龄在 12 至 64 岁之间且正在接受控制药物治疗的患者。将患者分为中重度持续性哮喘,并在 12 个月的加重识别期内进一步评估加重情况。有 1 次或多次加重(哮喘相关住院或急诊就诊或皮质类固醇处方)的患者按人口统计学特征和哮喘严重程度与无加重的患者进行匹配。计算了加重索引日期后 1 年研究期间的总健康护理成本和哮喘相关健康护理成本。

结果

有加重的患者的总健康护理成本($9223 比 $5011,P <.0001)和哮喘相关成本($1740 比 $847,P <.0001)显著更高。在使用多变量模型控制患者差异后,成本差异仍然显著。有加重的患者(n = 3830)在基线时患有鼻窦炎、过敏相关诊断或药物、肺炎和精神障碍的比例更高,平均 Charlson 合并症指数评分更高。有加重的患者更频繁地开具控制器处方,且哮喘相关药物成本更高。

结论

有哮喘加重的中重度持续性哮喘患者的总健康护理成本和哮喘相关健康护理成本均高于无加重的患者。此外,有加重的患者的控制器药物使用量更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验